Literature DB >> 34170480

Risk prediction for delayed clearance of high-dose methotrexate in pediatric hematological malignancies by machine learning.

Min Zhan1, Zebin Chen1, Changcai Ding2, Qiang Qu3, Guoqiang Wang1, Sixi Liu4, Feiqiu Wen5.   

Abstract

This study aimed to establish a predictive model to identify children with hematologic malignancy at high risk for delayed clearance of high-dose methotrexate (HD-MTX) based on machine learning. A total of 205 patients were recruited. Five variables (hematocrit, risk classification, dose, SLC19A1 rs2838958, sex) and three variables (SLC19A1 rs2838958, sex, dose) were statistically significant in univariable analysis and, separately, multivariate logistic regression. The data was randomly split into a "training cohort" and a "validation cohort". A nomogram for prediction of delayed HD-MTX clearance was constructed using the three variables in the training dataset and validated in the validation dataset. Five machine learning algorithms (cart classification and regression trees, naïve Bayes, support vector machine, random forest, C5.0 decision tree) combined with different resampling methods were used for model building with five or three variables. When developed machine learning models were evaluated in the validation dataset, the C5.0 decision tree combined with the synthetic minority oversampling technique (SMOTE) using five variables had the highest area under the receiver operating characteristic curve (AUC 0.807 [95% CI 0.724-0.889]), a better performance than the nomogram (AUC 0.69 [95% CI 0.594-0.787]). The results support potential clinical application of machine learning for patient risk classification.

Entities:  

Keywords:  Machine learning; Methotrexate clearance; Pediatric hematological malignancies; Pharmacogenomics; SNP genotyping

Year:  2021        PMID: 34170480     DOI: 10.1007/s12185-021-03184-w

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  45 in total

Review 1.  Methotrexate Disposition in Pediatric Patients with Acute Lymphoblastic Leukemia: What Have We Learnt From the Genetic Variants of Drug Transporters.

Authors:  Ya-Hui Hu; Lin Zhou; Shan-Shan Wang; Xia Jing; Hong-Li Guo; Fang Sun; Yong Zhang; Feng Chen; Jing Xu; Xing Ji
Journal:  Curr Pharm Des       Date:  2019       Impact factor: 3.116

Review 2.  Biology, risk stratification, and therapy of pediatric acute leukemias: an update.

Authors:  Ching-Hon Pui; William L Carroll; Soheil Meshinchi; Robert J Arceci
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

3.  Plasma creatinine as predictor of delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia: A Danish population-based study.

Authors:  Diana Schmidt; Kim Kristensen; Henrik Schroeder; Peder Skov Wehner; Steen Rosthøj; Jesper Heldrup; Linn Damsgaard; Kjeld Schmiegelow; Torben Stamm Mikkelsen
Journal:  Pediatr Blood Cancer       Date:  2019-03-05       Impact factor: 3.167

Review 4.  Pharmacokinetic drug-drug interactions with methotrexate in oncology.

Authors:  Dominique Levêque; Raoul Santucci; Bénédicte Gourieux; Raoul Herbrecht
Journal:  Expert Rev Clin Pharmacol       Date:  2011-11       Impact factor: 5.045

Review 5.  Pharmacogenomics of Methotrexate: Current Status and Future Outlook.

Authors:  Mengda Cao; Miao Guo; De-Qin Wu; Ling Meng
Journal:  Curr Drug Metab       Date:  2018       Impact factor: 3.731

Review 6.  Clinical Implications of Methotrexate Pharmacogenetics in Childhood Acute Lymphoblastic Leukaemia.

Authors:  Guillermo Gervasini; Sonia Mota-Zamorano
Journal:  Curr Drug Metab       Date:  2019       Impact factor: 3.731

Review 7.  Treatment of childhood acute lymphoblastic leukemia.

Authors:  Martin Stanulla; Martin Schrappe
Journal:  Semin Hematol       Date:  2009-01       Impact factor: 3.851

8.  Delayed methotrexate elimination: Incidence, interaction with antacid drugs, and clinical consequences?

Authors:  Florence Ranchon; Nicolas Vantard; Emilie Henin; Emmanuel Bachy; Clémentine Sarkozy; Lionel Karlin; Fadhela Bouafia-Sauvy; Aurore Gouraud; Verane Schwiertz; Estelle Bourbon; Amandine Baudouin; Anne Gaelle Caffin; Thierry Vial; Gilles Salles; Catherine Rioufol
Journal:  Hematol Oncol       Date:  2017-10-06       Impact factor: 5.271

Review 9.  Preventing and Managing Toxicities of High-Dose Methotrexate.

Authors:  Scott C Howard; John McCormick; Ching-Hon Pui; Randall K Buddington; R Donald Harvey
Journal:  Oncologist       Date:  2016-08-05

10.  Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance.

Authors:  Laura B Ramsey; Frank M Balis; Maureen M O'Brien; Kjeld Schmiegelow; Jennifer L Pauley; Archie Bleyer; Brigitte C Widemann; David Askenazi; Sharon Bergeron; Anushree Shirali; Stefan Schwartz; Alexander A Vinks; Jesper Heldrup
Journal:  Oncologist       Date:  2017-10-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.